In particular, more detailed data regarding how neurodegenerative disease–associated variants in TREM2 affect its structure and dynamics, and in turn its ability to bind ligands, would enable development of more precise therapeutics to target TREM2 in neurodegenerative disease. The gene discussed is TREM2; the disease is neurodegenerative disease.